G. Guyatt

Statistics and Probability · 2000–2022

A researcher in the Science corpus: 67 papers; trusts 9 researchers and is trusted by 17 researchers here, as inferred from the citation graph.

Subfields

Whom G. Guyatt trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Andrew D. Oxman
  2. Julian P. T. Higgins
  3. John P. A. Ioannidis
  4. Regina Kunz
  5. J. Deeks
  6. Douglas G. Altman
  7. J. Heit
  8. G. Vist
  9. Victor M. Montori
  10. P. Glasziou

Who trusts G. Guyatt overall

  1. Holger J. Schünemann
  2. J. Jakobsen
  3. J. Brożek
  4. Andrew D. Oxman
  5. Georgia Salanti
  6. Julian P. T. Higgins
  7. Adriani Nikolakopoulou
  8. M. Samuel
  9. Harry van Goor
  10. P. Moja

Papers from G. Guyatt's perspective

Ordered by how strongly the researchers G. Guyatt trusts endorse each paper. Same corpus, a different order for every researcher.

  1. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. (Journal of Clinical Epidemiology)
  2. GRADE guidelines: 2. Framing the question and deciding on important outcomes. (Journal of Clinical Epidemiology)
  3. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study (British medical journal)
  4. Selective publication of antidepressant trials and its influence on apparent efficacy. (New England Journal of Medicine)
  5. External validity of randomised controlled trials: "to whom do the results of this trial apply?".
  6. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. (Journal of the American Medical Association (JAMA))
  7. When are randomised trials unnecessary? Picking signal from noise (British medical journal)
  8. The safety of statins in clinical practice. (The Lancet)
  9. Pharmaceutical industry sponsorship and research outcome and quality: systematic review (British medical journal)
  10. Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications (British medical journal)

Their papers